EUROPEAN mediscience awards 2010

Sponsored by

nomination form 3. Individual: Please find enclosed your nomination form for the European Mediscience Awards Company: Dinner 2010, giving you the opportunity to nominate the companies and individuals you believe deserve recognition for outstanding success in their respective fields. Reason: The awards cover the period 1 April 2009 to 31 March 2010. You can nominate on‑line 5. transaction of the year at www.mediscience-event.co.uk, or please complete and return to Jo Thomas (jo. [email protected]). Sponsored by NASDAQ OMX The winner of this award will have completed a significant commercial or corporate Nominations close on Wednesday 12 May 2010. It would be most helpful if you could transaction during the period under review. This transaction would be transformational indicate where possible the reason for the nomination. in nature and would have added significantly to the company’s or organisation’s A list of eligible companies for the awards is overleaf. prospects. Name: Nominations: Position: 1. Individual: Company: Company: Tel: Date: Reason: e-mail: 2. Individual: Company: 1. best communication Sponsored by Capital MS&L Reason: Successful communication is vital to the development of mediscience companies. 3. Individual: Newsflow, both good and bad, can have a significant effect on share prices, and the Company: winner of this award will have demonstrated its ability to successfully communicate its investment message to its target audience. Reason: Nominations: 6. most significant contribution 1. Company: Sponsored by College Hill Reason: This could be an individual, a company, a government department, research council etc. who has made the single, biggest, most significant contribution to the sector. 2. Company: Although the awards are predominantly quoted company awards, the winner of this Reason: award could emerge from any related business, organisation or department which is 3. Company: involved in the European Mediscience sector. Therefore the criteria for this award is difficult to fully define, but the Voting Panel will be aware of, and make allowances for Reason: this fact. 2. breakthrough of the year Nominations: Sponsored by Matrix Corporate Capital LLP 1. Individual: The winner of this award will be the company or organisation which has achieved the Company/organisation: most significant breakthrough during the period 1 April 2009 to 31 March 2010. This breakthrough could be a new discovery, departure or breakthrough in technology, Reason: a significant positive change in its financial position, or other breakthrough which has 2. Individual: added significantly to the company’s or organisation’s fortunes. Company/organisation: Nominations: Reason: 1. Company/organisation: 3. Individual: Reason: Company/organisation: 2. Company/organisation: Reason: Reason: 3. Company/organisation: 7. chief executive of the year Sponsored by Buchanan Communications Reason: The winner will be an individual who has demonstrated exceptional leadership qualities during the year under review. The creation of shareholder value through 3. best technology drive, vision and flair in taking his or her business forward are the qualities the Voting Sponsored by Design Portfolio Marketing Services Panel are looking for. The winner will also have recognised the importance The technology that lies at the heart of this award does not have to be proven, but it of developing a management team and workforce in supporting corporate success. will, in the eyes of the Voting Panel, be innovative, well funded, will make a significant clinical/health impact and will be capable of significant commercial success. The Nominations: technology concerned could have been developed within the organisation, or 1. Individual: acquired. Company: Nominations: Reason: 1. Company: 2. Individual: Reason: Company: 2. Company: Reason: Reason: 3. Individual: 3. Company: Company: Reason: Reason: 4. mediscience commentator of the year 8. company of the year This award recognises the importance of clear and concise commentary on the sector. It could be awarded to an analyst, a journalist, a columnist, a research house, Sponsored by Piper Jaffray a specialist website or a team that is dedicated to providing sharp, perceptive and The company of the year will already have gained recognition by analysts and investors. penetrating commentary about the sector. In-depth knowledge of the sector is a given; It will be a well managed, soundly financed growth business with a well defined the Voting Panel will be looking for excellence in the way that knowledge strategy to deliver its key financial, ethical and social ambitions. Put simply, the Voting is communicated to the wider audience. Panel are not necessarily looking for the biggest, but they are looking for the best. Nominations: Nominations: 1. Individual: 1. Company: Company: Reason: Reason: 2. Company: 2. Individual: Reason: Company: 3. Company: Reason: Reason:

The menu has been sponsored by M Communications

00_LSM_NOM form 10.indd 1 14/04/2010 12:58:15 eligible companies

4SC AG DIAMYD MEDICAL AB OCTOPLUS NV ABBOTT LABORATORIES EASTPHARMA LTD OMEGA DIAGNOSTICS GROUP ABCAM ECO ANIMAL HEALTH GROUP ONCOMETHYLOME SCIENCES ABLYNX NV ELAN CORP ONDINE BIOPHARMA CORP ACTELION ENTELOS INC OPTOS ADDEX PHARMACEUTICALS LTD EPIGENOMICS AG OREXO AB AEROCRINE AB EPISTEM HLDGS ORION CORP AFFITECH AS E-THERAPEUTICS OSMETECH ADVANCED MEDICAL SOLUTIONS GROUP EUROCINE VACCINES AB OXFORD BIOMEDICA AGI THERAPEUTICS EVOTEC PAION AG AKERS BIOSCIENCES INC EXIQON A/S PCI BIOTECH HOLDINGS ASA ALGETA ASA EXONHIT THERAPEUTICS SA PFIZER INC ALK-ABELLO A/S FULCRUM PHARMA PHARMING GROUP NV ALLERGY THERAPEUTICS FUTURA MEDICAL PHARMSTANDARD OJSC ALLIANCE PHARMA GALAPAGOS NV PHOTOCURE ASA ALIGNA AG GENEART AG PHYSIOMICS ALPHAHELIX MOLECULAR DIAGNOSTICS NV GENFIT SA PHYTOPHARM AMSTERDAM MOLECULAR THERAPEUTICS NV GENMAB A/S PLETHORA SOLUTIONS HLDGS ANGEL BIOTECHNOLOGY GENOVIS AB PROSTRAKAN GROUP ANIMALCARE GROUP GENOWAY SA PROTEOME SCIENCES ANTISOMA GENUS PRONOVA BIOPHARM ASA AORTECH INTERNATIONAL GLAXOSMITHKLINE PROVEXUS AQUA BOUNTY TECHNOLOGIES INC GW PHARMACEUTICALS PROXIMAGEN NEUROSCIENCE ARK THERAPEUTICS GROUP HANSA MEDICAL AB PURICORE ARTIMPLANT AB H LUNDBECK QIAGEN NV ASTERAND HENDERSON MORLEY Q-MED AB ASTRAZENECA HIKMA PHARMACEUTICALS RANSOM (WILLIAM) & SON AVACTA GROUP HUTCHISON CHINA MEDITECH REGEN THERAPEUTICS AXIS-SHIELD HYBRIGENICS SA RELIANCE GENEMEDIX BASILEA PHARMACEUTICA AG IDL BIOTECH RENEURON GROUP BAVARIAN NORDIC A/S INNATE PHARMA SA RENISHAW BEXIMCO PHARMACEUTICALS IMMUNODIAGNOSTIC SYSTEMS HLDGS RENOVO GROUP BIOALLIANCE PHARMA IMMUPHARMA RESEARCH PHARMACEUTICAL SRV INC BIOCOMPATIBLES INTERNATIONAL INTERCELL BIOMEDICAL RESEARCH & DEVELOPMENT AG ROBOTIC TECHNOLOGY SYSTEMS BIOFRONTERA AG INTERNATIONAL BRACHYTHERAPY SA SANTHERA BIOINVENT INT AB IPSEN SA SAREUM HLDGS BIOLIN SCIENTIFIC AB IPSOGEN SA SCIENTIFIC DIGITAL IMAGING BIOMERIEUX SA IS PHARMA SHIRE BIOPORTO A/S KARO BIO AB SILENCE THERAPEUTICS BIOQUELL KIOTECH INTERNATIONAL SINCLAIR PHARMA BIOTAGE AB LIDCO GROUP SKYEPHARMA BIOTEC PHARMACON ASA LIFECYCLE PHARMA A/S SMITH & NEPHEW BIOTEST AG LIFELINE SCIENTIFIC INC SOURCE BIOSCIENCE BIOTIE THERAPIES OY LILLY (ELI) & CO STALLERGENES BIOVITRUM AB LIPOXEN STRATEC BIOMEDICAL SYSTEMS AG BIOXELL SpA LOMBARD MEDICAL TECHNOLOGIES SUMMIT CORP BTG MAGFORCE NANOTECH AG SURGICAL INNOVATIONS GROUP BYOTROL MEDA AB SYGNIS PHARMA AG CARCLO MEDGENICS INC SYNAIRGEN CATHAY INTERNATIONAL MEDICSIGHT SYNTOPIX GROUP CELLECTIS MEDIGENE AG TAIHUA CEREP SA MEDIVIR AB TECAN GROUP LTD CHEMOMETEC A/S MEDIWATCH THROMBOGENICS NV CHINA MEDICAL SYSTEM HLDGS MERRION PHARMACEUTICALS TOPOTARGET A/S CLAVIS PHARMA AS METABOLIC EXPLORER SA TRANSGENE SA CLEARSTREAM TECHNOLOGIES GROUP MOLOGEN HOLDINGS AG TRIPEP AB CODON AG MOLMED SpA TRISTEL CONPHARM MORPHOSYS AG UCB SA CONSORT MEDICAL MOVETIS NV ULTRASIS CORIN GROUP NASCACELL TECHNOLOGIES AG VALIRX COSMO PHARMACEUTICALS SpA NAVAMEDIC Asa VECTURA GROUP CREATIVE ANTIBIOTICS SWEDEN AB NEUROPHARM GROUP VERNALIS CRUCELL NEUROSEARCH A/S VERONA PHARMA CRYO-SAVE GROUP NV NEUTRAHEALTH VINDON HEALTHCARE CUSTOMVIS NEWRON PHARMA VIVALIS SA CYPROTEX NEXTGEN GROUP WILEX CYTOS BIOTECHNOLOGY AG NICOX SA XCOUNTER AB DECHRA PHARMACEUTICALS NORDIAG ASA YM BIOSCIENCES INC DELTEX MEDICAL GROUP NORTHWEST BIOTHERAPEUTICS INC YPSOMED HOLDINGS AG DIAGENIC ASA NOVO-NORDISK AS ZELTIA SA

00_LSM_NOM form 10.indd 2 14/04/2010 12:58:15